Insulet Set to Make Its Mark at Upcoming 2023 Investor Conferences

Insulet Corporation (NASDAQ: PODD) – the leader in cutting-edge tubeless insulin pump technology – is pleased to announce that its management team will be presenting at two upcoming investor conferences. The Omnipod® brand of products, developed by Insulet, is revolutionizing diabetes management, offering more control and freedom to those living with the condition. Don’t miss out on the opportunity to learn more about this innovative technology!

On Tuesday, March 7, 2023, join Raymond James & Associates at their 44th Annual Institutional Investors Conference in Orlando, FL! This is your chance to network with top investors and learn the latest insights in the field. Don’t miss out on this unique opportunity to gain the knowledge and expertise needed to take your investing to the next level. The conference will kick off at 9:15 a.m. (Eastern Time) – we look forward to seeing you there!

Join us at the Cowen 43rd Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2023! This event is an opportunity to hear from some of the industry’s leading experts and engage in meaningful dialogue about the latest healthcare trends and innovations. Don’t miss out on this chance to gain insight and connect with others in the field. The conference begins at 10:30 a.m. (Eastern Time).

About Insulet Corporation:

Insulet Corporation is an innovative medical device company revolutionizing the way we manage diabetes and other conditions. With its simple, wearable design, the Omnipod Insulin Management System provides up to three days of non-stop insulin delivery without the need to see or handle a needle. The latest innovation from Insulet, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system integrated with a continuous glucose monitor. This allows for blood sugar management with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet is also leveraging its unique Pod design to provide non-insulin subcutaneous drugs across other therapeutic areas.

Leave a Comment